Linaxitin
Generic Name
Linaxitin
Manufacturer
MediCorp Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| linaxitin 5 mg tablet | ৳ 15.00 | ৳ 225.00 |
Description
Overview of the medicine
Linaxitin 5 mg tablet is an oral antidiabetic medicine used to improve blood sugar control in adults with type 2 diabetes mellitus. It works by increasing the levels of certain natural substances (incretins) that help control blood sugar.
Uses & Indications
Dosage
Adults
The recommended dose is 5 mg once daily, taken orally with or without food.
Elderly
No dosage adjustment is required based on age.
Renal_impairment
No dosage adjustment is required for patients with renal impairment, including those on dialysis.
How to Take
Take Linaxitin 5 mg tablet orally once daily, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Linaxitin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the inactivation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Linaxitin increases the concentrations of active incretin hormones, which enhances glucose-dependent insulin secretion from pancreatic beta cells and decreases glucagon secretion from pancreatic alpha cells, leading to improved glycemic control.
Pharmacokinetics
Onset
Within 1-2 hours of administration.
Excretion
Primarily eliminated via the enterohepatic system (bile/feces), with approximately 80% of the dose excreted in feces and about 5% in urine. This minimal renal excretion makes it suitable for patients with renal impairment.
Half life
The terminal elimination half-life is approximately 100 hours, but the effective half-life for DPP-4 inhibition is about 12-24 hours, allowing for once-daily dosing.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations reached within 1.5 hours. Absolute bioavailability is approximately 30%.
Metabolism
Minimal metabolism, with a small fraction metabolized by CYP3A4. The primary elimination pathway is excretion of the unchanged drug.
Side Effects
Contraindications
- Hypersensitivity to linaxitin or any excipients in the tablet.
- Patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Drug Interactions
Digoxin
Linaxitin does not have a clinically meaningful effect on the pharmacokinetics of digoxin.
Rifampicin
Coadministration with rifampicin (a P-glycoprotein and CYP3A4 inducer) may decrease linaxitin exposure and efficacy. Consider alternative antidiabetic treatments if co-administration is necessary.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic treatment and supportive measures should be initiated as dictated by the patient’s clinical status. Linaxitin is unlikely to be removed by hemodialysis or peritoneal dialysis.
Pregnancy & Lactation
There are no adequate and well-controlled studies of linaxitin in pregnant women. Linaxitin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether linaxitin is excreted in human milk; therefore, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years from the date of manufacture.
Availability
Available in pharmacies and hospitals
Approval Status
FDA Approved
Patent Status
Patent protected
Clinical Trials
Linaxitin has undergone extensive Phase III clinical trials demonstrating its efficacy and safety in patients with type 2 diabetes, including those with renal impairment and cardiovascular risk factors.
Lab Monitoring
- Regular monitoring of HbA1c to assess glycemic control.
- Periodically monitor renal function, although no dose adjustment is needed for Linaxitin in renal impairment.
Doctor Notes
- Linaxitin is a valuable option for patients with type 2 diabetes, particularly those with renal impairment due to its minimal renal excretion.
- Advise patients to report any symptoms of pancreatitis (e.g., severe abdominal pain) or skin blistering promptly.
Patient Guidelines
- Take Linaxitin exactly as prescribed by your doctor.
- Do not stop taking Linaxitin without consulting your doctor.
- Maintain a healthy diet and regular exercise program as advised by your doctor.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Linaxitin is not known to affect the ability to drive or use machines. However, if used in combination with a sulfonylurea or insulin, there is a risk of hypoglycemia, which could impair driving ability.
Lifestyle Advice
- Follow a balanced diet low in sugar and saturated fats.
- Engage in regular physical activity as recommended by your healthcare provider.
- Monitor your blood glucose levels regularly as instructed.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
Related
Medicines
Explore similar medicines to find the best option for your healthcare needs.
Lotenate Plus
General Pharmaceuticals Ltd.
EuroORS
Euro Pharma Ltd.
Axxo
Square Pharmaceuticals Ltd.
Exopan
Square Pharmaceuticals Ltd.
Exib
Incepta Pharmaceuticals Ltd.
Avloquin-H
General Pharmaceuticals Ltd.
Evoloxin
Incepta Pharmaceuticals Ltd.
Exomi MUPS
Square Pharmaceuticals Ltd.
Azelec
Square Pharmaceuticals Ltd.
Exler
Incepta Pharmaceuticals